MD918Z - Метод лечения энтеровирусного менингита у детей - Google Patents
Метод лечения энтеровирусного менингита у детей Download PDFInfo
- Publication number
- MD918Z MD918Z MDS20140091A MDS20140091A MD918Z MD 918 Z MD918 Z MD 918Z MD S20140091 A MDS20140091 A MD S20140091A MD S20140091 A MDS20140091 A MD S20140091A MD 918 Z MD918 Z MD 918Z
- Authority
- MD
- Moldova
- Prior art keywords
- patients
- group
- children
- treatment
- glucopyranosyl
- Prior art date
Links
- 201000009906 Meningitis Diseases 0.000 title claims abstract description 17
- 238000000034 method Methods 0.000 title claims abstract description 10
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 13
- 238000001784 detoxification Methods 0.000 claims abstract description 6
- 230000001154 acute effect Effects 0.000 claims abstract description 5
- 230000001717 pathogenic effect Effects 0.000 claims abstract description 5
- 235000012054 meals Nutrition 0.000 claims abstract description 4
- 230000017531 blood circulation Effects 0.000 claims description 3
- 230000002490 cerebral effect Effects 0.000 claims description 3
- 235000021004 dietary regimen Nutrition 0.000 claims description 3
- 238000002636 symptomatic treatment Methods 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract description 3
- 235000005911 diet Nutrition 0.000 abstract description 2
- 230000009469 supplementation Effects 0.000 abstract description 2
- 210000000988 bone and bone Anatomy 0.000 abstract 1
- 230000003727 cerebral blood flow Effects 0.000 abstract 1
- 230000000378 dietary effect Effects 0.000 abstract 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 11
- 206010037660 Pyrexia Diseases 0.000 description 10
- 206010019233 Headaches Diseases 0.000 description 8
- 231100000869 headache Toxicity 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 6
- 230000002380 cytological effect Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 206010047700 Vomiting Diseases 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 238000010606 normalization Methods 0.000 description 4
- 230000002688 persistence Effects 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 230000008673 vomiting Effects 0.000 description 4
- 241000700605 Viruses Species 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 238000009593 lumbar puncture Methods 0.000 description 3
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 208000028041 Brudzinski sign Diseases 0.000 description 2
- 241000709661 Enterovirus Species 0.000 description 2
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 2
- 208000000112 Myalgia Diseases 0.000 description 2
- 206010037596 Pyelonephritis Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 206010042566 Superinfection Diseases 0.000 description 2
- 241001122767 Theaceae Species 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- 238000003759 clinical diagnosis Methods 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- LELAOEBVZLPXAZ-UHFFFAOYSA-N iberin Chemical compound CS(=O)CCCN=C=S LELAOEBVZLPXAZ-UHFFFAOYSA-N 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 206010044008 tonsillitis Diseases 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 description 1
- 208000005156 Dehydration Diseases 0.000 description 1
- 206010070971 Enteroviral infections Diseases 0.000 description 1
- 206010015958 Eye pain Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- DDNCQMVWWZOMLN-IRLDBZIGSA-N Vinpocetine Chemical compound C1=CC=C2C(CCN3CCC4)=C5[C@@H]3[C@]4(CC)C=C(C(=O)OCC)N5C2=C1 DDNCQMVWWZOMLN-IRLDBZIGSA-N 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 229940098164 augmentin Drugs 0.000 description 1
- 235000004251 balanced diet Nutrition 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229940119744 dextran 40 Drugs 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 210000004201 immune sera Anatomy 0.000 description 1
- 229940042743 immune sera Drugs 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 206010024378 leukocytosis Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 229940041033 macrolides Drugs 0.000 description 1
- 201000011475 meningoencephalitis Diseases 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 229960001476 pentoxifylline Drugs 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Изобретение относится к медицине, в частности к инфекционным болезням и может быть использовано для лечения энтеровирусного менингита у детей.Согласно изобретению, заявленный метод состоит в том, что выполняют основную терапию, которая включает соблюдение гигиенического режима, диеты, постельного режима в остром периоде, патогенетическое, симптоматическое, детоксификационное и для улучшения мозгового кровообращения лечение, при этом дополнительно перорально вводят 5α-фуростан-3β,22,26-триол-3-[O-β-D-глюкопиранозил-(1→2)-β-D-глюкопиранозил(1→4)-β-D-галактопиранозил]-26-O-β-D-глюкопиранозид), по 100 мг 2 раза в день, за 30 мин до еды, в течение 30 дней.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MDS20140091A MD918Z (ru) | 2014-06-18 | 2014-06-18 | Метод лечения энтеровирусного менингита у детей |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MDS20140091A MD918Z (ru) | 2014-06-18 | 2014-06-18 | Метод лечения энтеровирусного менингита у детей |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MD918Y MD918Y (ru) | 2015-06-30 |
| MD918Z true MD918Z (ru) | 2016-01-31 |
Family
ID=53487816
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MDS20140091A MD918Z (ru) | 2014-06-18 | 2014-06-18 | Метод лечения энтеровирусного менингита у детей |
Country Status (1)
| Country | Link |
|---|---|
| MD (1) | MD918Z (ru) |
-
2014
- 2014-06-18 MD MDS20140091A patent/MD918Z/ru not_active IP Right Cessation
Non-Patent Citations (1)
| Title |
|---|
| Protocol clinic naţional. Infecţia enterovirală la copii. Ministerul Sănătăţii al Republicii Moldova, Chişinău, 2012, p. * |
Also Published As
| Publication number | Publication date |
|---|---|
| MD918Y (ru) | 2015-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ANDERSON | Familial leukemia: A report of leukemia in five siblings, with a brief review of the genetic aspects of this disease | |
| Geier et al. | Thimerosal: clinical, epidemiologic and biochemical studies | |
| Flening | The presentation, management and prevention of crisis in sickle cell disease in Africa | |
| Siakwa et al. | Neonatal sepsis in rural Ghana: a case control study of risk factors in a birth cohort | |
| Kapila et al. | A review on: Hiv aids | |
| World Health Organization | Clinical management of patients with viral haemorrhagic fever: a pocket guide for front-line health workers. interim emergency guidance for Country adaption | |
| Endo et al. | Deep-vein thrombosis induced by tranexamic acid in idiopathic thrombocytopenic purpura | |
| WIENER et al. | Chromosome studies in retinoblastoma | |
| TWI581793B (zh) | 甲胂酸鈉ｓｏｄｉｕｍ ｍｅｔｈｙｌａｒｓｏｎａｔｅ作為病原體醣蛋白抑制劑之醫學新用途。 | |
| Benguigui et al. | Integrated management of childhood illness: an emphasis on the management of infectious diseases | |
| Long et al. | Profile of patients signing against medical advice | |
| Lamture Sr et al. | Stevens-Johnson Syndrome Induced by Herbal Kadha | |
| Horwitz et al. | Subacute bacterial endocarditis presenting as purpura | |
| Zwierzyńska et al. | HIV IN PREGNANCY WITHOUT TREATMENT: EFFECTS ON MOTHER AND CHILD-A CASE REPORT. | |
| Evans | Child with Fever and Rash | |
| Gimono | Anaemia in Pregnancy and Its Relation to Adverse Maternal-Fetal Outcomes and Risk Factors in Oman | |
| Medvedev | Evolution of AIDS policy in the Soviet Union. I. Serological screening 1986-7 | |
| Cregor et al. | Syphilotoxemia in the New-Born | |
| Afroze et al. | Congenital Dengue in a 5 Day Old Neonate | |
| Mustafa | Mother to child transmission (MTCT) Aids | |
| RU2392001C2 (ru) | Способ лечения желтушных форм вирусного гепатита а у детей с пищевой аллергией | |
| Sabiescu et al. | COVID-19 in a Pacient with HIV Inflection-A Case Study | |
| WHEAT | as Twenty pentosuric | |
| LIPMAN | Fatal virus hepatitis occurring in an infant three months of age | |
| Geethesh et al. | Thrombotic Thrombocytopenic Purpura Associated with Human Immunodeficiency Virus Infection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG9Y | Short term patent issued | ||
| MK4Y | Short term patent expired |